TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2017 DA - 2017// TI - Cancer statistics, 2017 JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21387 DO - 10.3322/caac.21387 ID - Siegel2017 ER - TY - JOUR AU - Tomiguchi, M. AU - Yamamoto, Y. AU - Yamamoto-Ibusuki, M. AU - Goto-Yamaguchi, L. AU - Fujiki, Y. AU - Fujiwara, S. PY - 2016 DA - 2016// TI - Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer JO - Cancer Sci VL - 107 UR - https://doi.org/10.1111/cas.12897 DO - 10.1111/cas.12897 ID - Tomiguchi2016 ER - TY - JOUR AU - Palmieri, D. AU - Bronder, J. L. AU - Herring, J. M. AU - Yoneda, T. AU - Weil, R. J. AU - Stark, A. M. PY - 2007 DA - 2007// TI - Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3316 DO - 10.1158/0008-5472.CAN-06-3316 ID - Palmieri2007 ER - TY - JOUR AU - Lemmon, M. A. AU - Schlessinger, J. PY - 2010 DA - 2010// TI - Cell signaling by receptor tyrosine kinases JO - Cell VL - 141 UR - https://doi.org/10.1016/j.cell.2010.06.011 DO - 10.1016/j.cell.2010.06.011 ID - Lemmon2010 ER - TY - JOUR AU - Templeton, A. J. AU - Diez-Gonzalez, L. AU - Ace, O. AU - Vera-Badillo, F. AU - Šeruga, B. AU - Jordán, J. PY - 2014 DA - 2014// TI - Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis JO - Cancer Treat Rev VL - 40 UR - https://doi.org/10.1016/j.ctrv.2014.08.003 DO - 10.1016/j.ctrv.2014.08.003 ID - Templeton2014 ER - TY - JOUR AU - Wise, R. AU - Zolkiewska, A. PY - 2017 DA - 2017// TI - Metalloprotease-dependent activation of EGFR modulates CD44+/CD24− populations in triple negative breast cancer cells through the MEK/ERK pathway JO - Breast Cancer Res Treat VL - 166 UR - https://doi.org/10.1007/s10549-017-4440-0 DO - 10.1007/s10549-017-4440-0 ID - Wise2017 ER - TY - JOUR AU - Park, J. AU - Kim, S. AU - Joh, J. AU - Remick, S. C. AU - Miller, D. M. AU - Yan, J. PY - 2016 DA - 2016// TI - MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.9759 DO - 10.18632/oncotarget.9759 ID - Park2016 ER - TY - JOUR AU - Qian, B. Z. AU - Zhang, H. AU - Li, J. AU - He, T. AU - Yeo, E. J. AU - Soong, D. Y. PY - 2015 DA - 2015// TI - FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis JO - J Exp Med VL - 212 UR - https://doi.org/10.1084/jem.20141555 DO - 10.1084/jem.20141555 ID - Qian2015 ER - TY - JOUR AU - Ibrahim, S. A. AU - Gadalla, R. AU - El-Ghonaimy, E. A. AU - Samir, O. AU - Mohamed, H. T. AU - Hassan, H. PY - 2017 DA - 2017// TI - Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways JO - Mol Cancer VL - 16 UR - https://doi.org/10.1186/s12943-017-0621-z DO - 10.1186/s12943-017-0621-z ID - Ibrahim2017 ER - TY - JOUR AU - Zhao, D. AU - Pan, C. AU - Sun, J. AU - Gilbert, C. AU - Drews-Elger, K. AU - Azzam, D. J. PY - 2015 DA - 2015// TI - VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 JO - Oncogene VL - 34 UR - https://doi.org/10.1038/onc.2014.257 DO - 10.1038/onc.2014.257 ID - Zhao2015 ER - TY - JOUR AU - Bussard, K. M. AU - Mutkus, L. AU - Stumpf, K. AU - Gomez-Manzano, C. AU - Marini, F. C. PY - 2016 DA - 2016// TI - Tumor-associated stromal cells as key contributors to the tumor microenvironment JO - Breast Cancer Res VL - 18 UR - https://doi.org/10.1186/s13058-016-0740-2 DO - 10.1186/s13058-016-0740-2 ID - Bussard2016 ER - TY - JOUR AU - Plantamura, I. AU - Casalini, P. AU - Dugnani, E. AU - Sasso, M. AU - D'ippolito, E. AU - Tortoreto, M. PY - 2014 DA - 2014// TI - PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells JO - Mol Oncol VL - 8 UR - https://doi.org/10.1016/j.molonc.2014.03.015 DO - 10.1016/j.molonc.2014.03.015 ID - Plantamura2014 ER - TY - JOUR AU - D'Ippolito, E. AU - Plantamura, I. AU - Bongiovanni, L. AU - Casalini, P. AU - Baroni, S. AU - Piovan, C. PY - 2016 DA - 2016// TI - miR-9 and miR-200 regulate PDGFRβ-mediated endothelial differentiation of tumor cells in triple-negative breast cancer JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-16-0140 DO - 10.1158/0008-5472.CAN-16-0140 ID - D'Ippolito2016 ER - TY - JOUR AU - He, M. AU - Wei, M. J. PY - 2012 DA - 2012// TI - Reversing multidrug resistance by tyrosine kinase inhibitors JO - Chin J Cancer VL - 31 UR - https://doi.org/10.5732/cjc.011.10315 DO - 10.5732/cjc.011.10315 ID - He2012 ER - TY - JOUR AU - Huang, L. AU - Fu, L. PY - 2015 DA - 2015// TI - Mechanisms of resistance to EGFR tyrosine kinase inhibitors JO - Acta Pharm Sin B VL - 5 UR - https://doi.org/10.1016/j.apsb.2015.07.001 DO - 10.1016/j.apsb.2015.07.001 ID - Huang2015 ER - TY - JOUR AU - Shrivastava, A. AU - Radziejewski, C. AU - Campbell, E. AU - Kovac, L. AU - McGlynn, M. AU - Ryan, T. E. PY - 1997 DA - 1997// TI - An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors JO - Mol Cell VL - 1 UR - https://doi.org/10.1016/S1097-2765(00)80004-0 DO - 10.1016/S1097-2765(00)80004-0 ID - Shrivastava1997 ER - TY - JOUR AU - Clayton, A. H. AU - Walker, F. AU - Orchard, S. G. AU - Henderson, C. AU - Fuchs, D. AU - Rothacker, J. PY - 2005 DA - 2005// TI - Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis JO - J Biol Chem VL - 280 UR - https://doi.org/10.1074/jbc.M504770200 DO - 10.1074/jbc.M504770200 ID - Clayton2005 ER - TY - JOUR AU - Ward, C. W. AU - Lawrence, M. C. AU - Streltsov, V. A. AU - Adams, T. E. AU - McKern, N. M. PY - 2007 DA - 2007// TI - The insulin and EGF receptor structures: new insights into ligand-induced receptor activation JO - Trends Biochem Sci VL - 32 UR - https://doi.org/10.1016/j.tibs.2007.01.001 DO - 10.1016/j.tibs.2007.01.001 ID - Ward2007 ER - TY - JOUR AU - Wiesmann, C. AU - Ultsch, M. H. AU - Bass, S. H. AU - de Vos, A. M. PY - 1999 DA - 1999// TI - Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor JO - Nature VL - 401 UR - https://doi.org/10.1038/43705 DO - 10.1038/43705 ID - Wiesmann1999 ER - TY - JOUR AU - Wehrman, T. AU - He, X. AU - Raab, B. AU - Dukipatti, A. AU - Blau, H. AU - Garcia, K. C. PY - 2007 DA - 2007// TI - Structural and mechanistic insights into nerve growth factor interactions with the TrkA and p75 receptors JO - Neuron VL - 53 UR - https://doi.org/10.1016/j.neuron.2006.09.034 DO - 10.1016/j.neuron.2006.09.034 ID - Wehrman2007 ER - TY - JOUR AU - Burgess, A. W. AU - Cho, H. S. AU - Eigenbrot, C. AU - Ferguson, K. M. AU - Garrett, T. P. AU - Leahy, D. J. PY - 2003 DA - 2003// TI - An open-and-shut case?Recent insights into the activation of EGF/ErbB receptors JO - Mol Cell VL - 12 UR - https://doi.org/10.1016/S1097-2765(03)00350-2 DO - 10.1016/S1097-2765(03)00350-2 ID - Burgess2003 ER - TY - JOUR AU - Yuzawa, S. AU - Opatowsky, Y. AU - Zhang, Z. AU - Mandiyan, V. AU - Lax, I. AU - Schlessinger, J. PY - 2007 DA - 2007// TI - Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor JO - Cell VL - 130 UR - https://doi.org/10.1016/j.cell.2007.05.055 DO - 10.1016/j.cell.2007.05.055 ID - Yuzawa2007 ER - TY - JOUR AU - Schlessinger, J. AU - Plotnikov, A. N. AU - Ibrahimi, O. A. AU - Eliseenkova, A. V. AU - Yeh, B. K. AU - Yayon, A. PY - 2000 DA - 2000// TI - Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization JO - Mol Cell VL - 6 UR - https://doi.org/10.1016/S1097-2765(00)00073-3 DO - 10.1016/S1097-2765(00)00073-3 ID - Schlessinger2000 ER - TY - JOUR AU - Huse, M. AU - Kuriyan, J. PY - 2002 DA - 2002// TI - The conformational plasticity of protein kinases JO - Cell VL - 109 UR - https://doi.org/10.1016/S0092-8674(02)00741-9 DO - 10.1016/S0092-8674(02)00741-9 ID - Huse2002 ER - TY - JOUR AU - Hubbard, S. R. PY - 2004 DA - 2004// TI - Juxtamembrane autoinhibition in receptor tyrosine kinases JO - Nat Rev Mol Cell Biol VL - 5 UR - https://doi.org/10.1038/nrm1399 DO - 10.1038/nrm1399 ID - Hubbard2004 ER - TY - JOUR AU - Griffith, J. AU - Black, J. AU - Faerman, C. AU - Swenson, L. AU - Wynn, M. AU - Lu, F. PY - 2004 DA - 2004// TI - The structural basis for autoinhibition of FLT3 by the juxtamembrane domain JO - Mol Cell VL - 13 UR - https://doi.org/10.1016/S1097-2765(03)00505-7 DO - 10.1016/S1097-2765(03)00505-7 ID - Griffith2004 ER - TY - JOUR AU - Till, J. H. AU - Becerra, M. AU - Watty, A. AU - Lu, Y. AU - Ma, Y. AU - Neubert, T. A. PY - 2002 DA - 2002// TI - Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation JO - Structure VL - 10 UR - https://doi.org/10.1016/S0969-2126(02)00814-6 DO - 10.1016/S0969-2126(02)00814-6 ID - Till2002 ER - TY - JOUR AU - Mol, C. D. AU - Dougan, D. R. AU - Schneider, T. R. AU - Skene, R. J. AU - Kraus, M. L. AU - Scheibe, D. N. PY - 2004 DA - 2004// TI - Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M403319200 DO - 10.1074/jbc.M403319200 ID - Mol2004 ER - TY - JOUR AU - Pawson, T. PY - 2007 DA - 2007// TI - Dynamic control of signaling by modular adaptor proteins JO - Curr Opin Cell Biol VL - 19 UR - https://doi.org/10.1016/j.ceb.2007.02.013 DO - 10.1016/j.ceb.2007.02.013 ID - Pawson2007 ER - TY - CHAP AU - Harris, R. C. AU - Chung, E. AU - Coffey, R. J. ED - Carpenter, G. PY - 2004 DA - 2004// TI - EGF receptor ligands BT - The EGF receptor family biologic mechanisms and role in cancer PB - Elsevier CY - California ID - Harris2004 ER - TY - JOUR AU - Freed, D. M. AU - Bessman, N. J. AU - Kiyatkin, A. AU - Salazar-Cavazos, E. AU - Byrne, P. O. AU - Moore, J. O. PY - 2017 DA - 2017// TI - EGFR ligands differentially stabilize receptor dimers to specify signaling kinetics JO - Cell VL - 171 UR - https://doi.org/10.1016/j.cell.2017.09.017 DO - 10.1016/j.cell.2017.09.017 ID - Freed2017 ER - TY - JOUR AU - Hu, H. AU - Liu, Y. AU - Jiang, T. PY - 2015 DA - 2015// TI - Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis JO - Tumour Biol VL - 36 UR - https://doi.org/10.1007/s13277-015-3287-4 DO - 10.1007/s13277-015-3287-4 ID - Hu2015 ER - TY - JOUR AU - van Rhijn, B. W. AU - van Tilborg, A. A. AU - Lurkin, I. AU - Bonaventure, J. AU - de Vries, A. AU - Thiery, J. P. PY - 2002 DA - 2002// TI - Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders JO - Eur J Hum Genet VL - 10 UR - https://doi.org/10.1038/sj.ejhg.5200883 DO - 10.1038/sj.ejhg.5200883 ID - van Rhijn2002 ER - TY - JOUR AU - Wagner, J. P. AU - Wolf-Yadlin, A. AU - Sevecka, M. AU - Grenier, J. K. AU - Root, D. E. AU - Lauffenburger, D. A. PY - 2013 DA - 2013// TI - Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks JO - Sci Signal VL - 6 UR - https://doi.org/10.1126/scisignal.2003994 DO - 10.1126/scisignal.2003994 ID - Wagner2013 ER - TY - JOUR AU - Al-Hajj, M. AU - Wicha, M. S. AU - Benito-Hernandez, A. AU - Morrison, S. J. AU - Clarke, M. F. PY - 2003 DA - 2003// TI - Prospective identification of tumorigenic breast cancer cells JO - Proc Natl AcadSci USA VL - 100 UR - https://doi.org/10.1073/pnas.0530291100 DO - 10.1073/pnas.0530291100 ID - Al-Hajj2003 ER - TY - JOUR AU - Ginestier, C. AU - Hur, M. H. AU - Charafe-Jauffret, E. AU - Monville, F. AU - Dutcher, J. AU - Brown, M. PY - 2007 DA - 2007// TI - ALDHI is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome JO - Cell Stem Cell VL - 1 UR - https://doi.org/10.1016/j.stem.2007.08.014 DO - 10.1016/j.stem.2007.08.014 ID - Ginestier2007 ER - TY - JOUR AU - Liu, S. AU - Cong, Y. AU - Wang, D. AU - Sun, Y. AU - Deng, L. AU - Liu, Y. PY - 2013 DA - 2013// TI - Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts JO - Stem Cell Rep VL - 2 UR - https://doi.org/10.1016/j.stemcr.2013.11.009 DO - 10.1016/j.stemcr.2013.11.009 ID - Liu2013 ER - TY - JOUR AU - Shibuya, M. PY - 2011 DA - 2011// TI - Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti-and pro-angiogenic therapies JO - Genes Cancer VL - 2 UR - https://doi.org/10.1177/1947601911423031 DO - 10.1177/1947601911423031 ID - Shibuya2011 ER - TY - JOUR AU - Yu, F. AU - Yao, H. AU - Zhu, P. AU - Zhang, X. AU - Pan, Q. AU - Gong, C. PY - 2007 DA - 2007// TI - let-7 regulates self renewal and tumorigenicity of breast cancer cells JO - Cell VL - 131 UR - https://doi.org/10.1016/j.cell.2007.10.054 DO - 10.1016/j.cell.2007.10.054 ID - Yu2007 ER - TY - JOUR AU - Tanei, T. AU - Morimoto, K. AU - Shimazu, K. AU - Kim, S. J. AU - Tanji, Y. AU - Taguchi, T. PY - 2009 DA - 2009// TI - Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-08-1479 DO - 10.1158/1078-0432.CCR-08-1479 ID - Tanei2009 ER - TY - JOUR AU - Nakayama, A. AU - Takagi, S. AU - Yusa, T. AU - Yaguchi, M. AU - Hayashi, A. AU - Tamura, T. PY - 2013 DA - 2013// TI - Antitumor activity of TAK-285, an investigational, non-Pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model JO - J Cancer VL - 4 UR - https://doi.org/10.7150/jca.6689 DO - 10.7150/jca.6689 ID - Nakayama2013 ER - TY - JOUR AU - Mayer, A. AU - Takimoto, M. AU - Fritz, E. AU - Schellander, G. AU - Kofler, K. AU - Ludwig, H. PY - 1993 DA - 1993// TI - The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer JO - Cancer VL - 71 UR - https://doi.org/3.0.CO;2-2 DO - 3.0.CO;2-2 ID - Mayer1993 ER - TY - JOUR AU - Jin, Y. AU - Zhang, W. AU - Xu, J. AU - Wang, H. AU - Zhang, Z. AU - Chu, C. PY - 2015 DA - 2015// TI - UCH-L1 involved in regulating the degradation of EGFR and promoting malignant properties in drug-resistant breast cancer JO - Int J Clin Exp Pathol VL - 8 ID - Jin2015 ER - TY - JOUR AU - Lee, H. J. AU - Seo, A. N. AU - Kim, E. J. AU - Jang, M. H. AU - Kim, Y. J. AU - Kim, J. H. PY - 2015 DA - 2015// TI - Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer JO - Br J Cancer VL - 112 UR - https://doi.org/10.1038/bjc.2014.556 DO - 10.1038/bjc.2014.556 ID - Lee2015 ER - TY - JOUR AU - Park, H. S. AU - Jang, M. H. AU - Kim, E. J. AU - Kim, H. J. AU - Lee, H. J. AU - Kim, Y. J. PY - 2014 DA - 2014// TI - High EGFR gene copy number predicts poor outcome in triple-negative breast cancer JO - Mod Pathol VL - 27 UR - https://doi.org/10.1038/modpathol.2013.251 DO - 10.1038/modpathol.2013.251 ID - Park2014 ER - TY - JOUR AU - Wilson, K. J. AU - Gilmore, J. L. AU - Foley, J. AU - Lemmon, M. A. AU - Riese, D. J. PY - 2009 DA - 2009// TI - Functional selectivity of EGF family peptide growth factors: implications for cancer JO - Pharmacol Ther VL - 122 UR - https://doi.org/10.1016/j.pharmthera.2008.11.008 DO - 10.1016/j.pharmthera.2008.11.008 ID - Wilson2009 ER - TY - JOUR AU - Macdonald-Obermann, J. L. AU - Pike, L. J. PY - 2014 DA - 2014// TI - Different epidermal growth factor (EGF) receptor ligands show distinct kinetics and biased or partial agonism for homodimer and heterodimer formation JO - J Biol Chem VL - 289 UR - https://doi.org/10.1074/jbc.M114.586826 DO - 10.1074/jbc.M114.586826 ID - Macdonald-Obermann2014 ER - TY - JOUR AU - Witton, C. J. AU - Reeves, J. R. AU - Going, J. J. AU - Cooke, T. G. AU - Bartlett, J. PY - 2003 DA - 2003// TI - Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer JO - J Pathol VL - 200 UR - https://doi.org/10.1002/path.1370 DO - 10.1002/path.1370 ID - Witton2003 ER - TY - JOUR AU - Price, J. T. AU - Tiganis, T. AU - Agarwal, A. AU - Djakiew, D. AU - Thompson, E. W. PY - 1999 DA - 1999// TI - Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3′-kinase and phospholipase C-dependent mechanism JO - Cancer Res VL - 59 ID - Price1999 ER - TY - JOUR AU - Silva, C. M. PY - 2004 DA - 2004// TI - Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1208159 DO - 10.1038/sj.onc.1208159 ID - Silva2004 ER - TY - JOUR AU - Zheng, Z. AU - Shao, N. AU - Weng, H. AU - Li, W. AU - Zhang, J. AU - Zhang, L. PY - 2015 DA - 2015// TI - Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma JO - Med Oncol VL - 32 UR - https://doi.org/10.1007/s12032-014-0275-2 DO - 10.1007/s12032-014-0275-2 ID - Zheng2015 ER - TY - JOUR AU - Hance, K. W. AU - Anderson, W. F. AU - Devesa, S. S. AU - Young, H. A. AU - Levine, P. H. PY - 2005 DA - 2005// TI - Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute JO - J Natl Cancer Inst VL - 97 UR - https://doi.org/10.1093/jnci/dji172 DO - 10.1093/jnci/dji172 ID - Hance2005 ER - TY - JOUR AU - Charafe-Jauffret, E. AU - Ginestier, C. AU - Iovino, F. AU - Tarpin, C. AU - Diebel, M. AU - Esterni, B. PY - 2010 DA - 2010// TI - Aldehyde dehydrogenase 1–Positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer JO - Clin Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-1630 DO - 10.1158/1078-0432.CCR-09-1630 ID - Charafe-Jauffret2010 ER - TY - JOUR AU - Van Laere, S. J. AU - Van der Auwera, I. AU - Van den Eynden, G. G. AU - Van Dam, P. AU - Van Marck, E. A. AU - Vermeulen, P. B. PY - 2007 DA - 2007// TI - NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation JO - Br J Cancer VL - 97 UR - https://doi.org/10.1038/sj.bjc.6603906 DO - 10.1038/sj.bjc.6603906 ID - Van Laere2007 ER - TY - JOUR AU - Wang, X. AU - Reyes, M. E. AU - Zhang, D. AU - Funakoshi, Y. AU - Trape, A. P. AU - Gong, Y. PY - 2017 DA - 2017// TI - EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer JO - Oncotarget VL - 8 ID - Wang2017 ER - TY - JOUR AU - Tian, M. AU - Schiemann, W. P. PY - 2017 DA - 2017// TI - TGF-β stimulation of EMT programs elicits non-genomic ER-α activity and anti-estrogen resistance in breast cancer cells JO - J Cancer Metastasis Treat VL - 3 UR - https://doi.org/10.20517/2394-4722.2017.38 DO - 10.20517/2394-4722.2017.38 ID - Tian2017 ER - TY - JOUR AU - Yeo, S. K. AU - Wen, J. AU - Chen, S. AU - Guan, J. L. PY - 2016 DA - 2016// TI - Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfβ/Smad signaling JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-15-2946 DO - 10.1158/0008-5472.CAN-15-2946 ID - Yeo2016 ER - TY - JOUR AU - Holdman, X. B. AU - Welte, T. AU - Rajapakshe, K. AU - Pond, A. AU - Coarfa, C. AU - Mo, Q. PY - 2015 DA - 2015// TI - Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer JO - Breast Cancer Res VL - 17 UR - https://doi.org/10.1186/s13058-015-0649-1 DO - 10.1186/s13058-015-0649-1 ID - Holdman2015 ER - TY - JOUR AU - Yang, J. AU - Liao, D. AU - Chen, C. AU - Liu, Y. AU - Chuang, T. H. AU - Xiang, R. PY - 2013 DA - 2013// TI - Tumor-associated macrophages regulate murine breast cancer stem cells through a novel paracrine EGFR/Stat3/Sox-2 signaling pathway JO - Stem Cells VL - 31 UR - https://doi.org/10.1002/stem.1281 DO - 10.1002/stem.1281 ID - Yang2013 ER - TY - JOUR AU - Alitalo, K. AU - Carmeliet, P. PY - 2002 DA - 2002// TI - Molecular mechanisms of lymphangiogenesis in health and disease JO - Cancer Cell VL - 1 UR - https://doi.org/10.1016/S1535-6108(02)00051-X DO - 10.1016/S1535-6108(02)00051-X ID - Alitalo2002 ER - TY - JOUR AU - Laakkonen, P. AU - Waltari, M. AU - Holopainen, T. AU - Takahashi, T. AU - Pytowski, B. AU - Steiner, P. PY - 2007 DA - 2007// TI - Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-3567 DO - 10.1158/0008-5472.CAN-06-3567 ID - Laakkonen2007 ER - TY - JOUR AU - Chakraborty, G. AU - Jain, S. AU - Kundu, G. C. PY - 2008 DA - 2008// TI - Osteopontin promotes vascular endothelial growth factor–dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-2126 DO - 10.1158/0008-5472.CAN-07-2126 ID - Chakraborty2008 ER - TY - JOUR AU - Srabovic, N. AU - Mujagic, Z. AU - Mujanovic-Mustedanagic, J. AU - Softic, A. AU - Muminovic, Z. AU - Rifatbegovic, A. PY - 2013 DA - 2013// TI - Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor a JO - Int J Breast Cancer VL - 2013 UR - https://doi.org/10.1155/2013/746749 DO - 10.1155/2013/746749 ID - Srabovic2013 ER - TY - JOUR AU - Kosaka, Y. AU - Kataoka, A. AU - Yamaguchi, H. AU - Ueo, H. AU - Akiyoshi, S. AU - Sengoku, N. PY - 2012 DA - 2012// TI - Vascular endothelial growth factor receptor-1 mRNA overexpression in peripheral blood as a useful prognostic marker in breast cancer JO - Breast Cancer Res VL - 14 UR - https://doi.org/10.1186/bcr3345 DO - 10.1186/bcr3345 ID - Kosaka2012 ER - TY - JOUR AU - Kapahi, R. AU - Guleria, K. AU - Sambyal, V. AU - Manjari, M. AU - Sudan, M. AU - Uppal, M. S. PY - 2015 DA - 2015// TI - Association of VEGF and VEGFR1 polymorphisms with breast cancer risk in North Indians JO - Tumour Biol VL - 36 UR - https://doi.org/10.1007/s13277-015-3059-1 DO - 10.1007/s13277-015-3059-1 ID - Kapahi2015 ER - TY - JOUR AU - Ning, Q. AU - Liu, C. AU - Hou, L. AU - Meng, M. AU - Zhang, X. AU - Luo, M. PY - 2013 DA - 2013// TI - Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition JO - PLoS One VL - 8 UR - https://doi.org/10.1371/journal.pone.0065217 DO - 10.1371/journal.pone.0065217 ID - Ning2013 ER - TY - JOUR AU - Incio, J. AU - Tam, J. AU - Rahbari, N. N. AU - Suboj, P. AU - McManus, D. T. AU - Chin, S. M. PY - 2016 DA - 2016// TI - PlGF/VEGFR-1 signaling promotes macrophage polarization and accelerated tumor progression in obesity JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1839 DO - 10.1158/1078-0432.CCR-15-1839 ID - Incio2016 ER - TY - JOUR AU - Chen, X. W. AU - Yu, T. J. AU - Zhang, J. AU - Li, Y. AU - Chen, H. L. AU - Yang, G. F. PY - 2017 DA - 2017// TI - CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis JO - Oncogene VL - 36 UR - https://doi.org/10.1038/onc.2017.118 DO - 10.1038/onc.2017.118 ID - Chen2017 ER - TY - JOUR AU - Guo, S. AU - Colbert, L. S. AU - Fuller, M. AU - Zhang, Y. AU - Gonzalez-Perez, R. R. PY - 2010 DA - 2010// TI - Vascular endothelial growth factor receptor-2 in breast cancer JO - Biochim Biophys Acta VL - 1806 ID - Guo2010 ER - TY - JOUR AU - Pfister, N. T. AU - Fomin, V. AU - Regunath, K. AU - Zhou, J. Y. AU - Zhou, W. AU - Silwal-Pandit, L. PY - 2015 DA - 2015// TI - Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells JO - Genes Dev VL - 29 UR - https://doi.org/10.1101/gad.263202.115 DO - 10.1101/gad.263202.115 ID - Pfister2015 ER - TY - JOUR AU - Jahangiri, A. AU - Nguyen, A. AU - Chandra, A. AU - Sidorov, M. K. AU - Yagnik, G. AU - Rick, J. PY - 2017 DA - 2017// TI - Cross-activating c-Met/β1 integrin complex drives metastasis and invasive resistance in cancer JO - Proc Natl Acad Sci VL - 114 ID - Jahangiri2017 ER - TY - JOUR AU - Schoppmann, S. F. AU - Bayer, G. AU - Aumayr, K. AU - Taucher, S. AU - Geleff, S. AU - Rudas, M. PY - 2004 DA - 2004// TI - Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer JO - Ann Surg VL - 240 UR - https://doi.org/10.1097/01.sla.0000133355.48672.22 DO - 10.1097/01.sla.0000133355.48672.22 ID - Schoppmann2004 ER - TY - JOUR AU - Tutunea-Fatan, E. AU - Majumder, M. AU - Xin, X. AU - Lala, P. K. PY - 2015 DA - 2015// TI - The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis JO - Mol Cancer VL - 14 UR - https://doi.org/10.1186/s12943-015-0306-4 DO - 10.1186/s12943-015-0306-4 ID - Tutunea-Fatan2015 ER - TY - JOUR AU - Timoshenko, A. V. AU - Chakraborty, C. AU - Wagner, G. F. AU - Lala, P. K. PY - 2006 DA - 2006// TI - COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6603067 DO - 10.1038/sj.bjc.6603067 ID - Timoshenko2006 ER - TY - JOUR AU - Lyons, T. R. AU - Borges, V. F. AU - Betts, C. B. AU - Guo, Q. AU - Kapoor, P. AU - Martinson, H. A. PY - 2014 DA - 2014// TI - Cyclooxygenase-2–dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer JO - J Clin Invest VL - 124 UR - https://doi.org/10.1172/JCI73777 DO - 10.1172/JCI73777 ID - Lyons2014 ER - TY - JOUR AU - Chen, W. S. AU - Cao, Z. AU - Sugaya, S. AU - Lopez, M. J. AU - Sendra, V. G. AU - Laver, N. PY - 2016 DA - 2016// TI - Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3 JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11302 DO - 10.1038/ncomms11302 ID - Chen2016 ER - TY - JOUR AU - Heldin, C. H. PY - 2013 DA - 2013// TI - Targeting the PDGF signaling pathway in tumor treatment JO - Cell Commun Signal VL - 11 UR - https://doi.org/10.1186/1478-811X-11-97 DO - 10.1186/1478-811X-11-97 ID - Heldin2013 ER - TY - JOUR AU - Carvalho, I. AU - Milanezi, F. AU - Martins, A. AU - Reis, R. M. AU - Schmitt, F. PY - 2005 DA - 2005// TI - Overexpression of platelet-derived growth factor receptor α in breast cancer is associated with tumour progression JO - Breast Cancer Res VL - 7 UR - https://doi.org/10.1186/bcr1304 DO - 10.1186/bcr1304 ID - Carvalho2005 ER - TY - JOUR AU - Bhardwaj, B. AU - Klassen, J. AU - Cossette, N. AU - Sterns, E. AU - Tuck, A. AU - Deeley, R. PY - 1996 DA - 1996// TI - Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma JO - Clin Cancer Res VL - 2 ID - Bhardwaj1996 ER - TY - JOUR AU - Paulsson, J. AU - Sjöblom, T. AU - Micke, P. AU - Pontén, F. AU - Landberg, G. AU - Heldin, C. H. PY - 2009 DA - 2009// TI - Prognostic significance of stromal platelet-derived growth factor β-receptor expression in human breast cancer JO - Am J Pathol VL - 175 UR - https://doi.org/10.2353/ajpath.2009.081030 DO - 10.2353/ajpath.2009.081030 ID - Paulsson2009 ER - TY - JOUR AU - Pinto, M. P. AU - Dye, W. W. AU - Jacobsen, B. M. AU - Horwitz, K. B. PY - 2014 DA - 2014// TI - Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling JO - BMC Cancer VL - 14 UR - https://doi.org/10.1186/1471-2407-14-735 DO - 10.1186/1471-2407-14-735 ID - Pinto2014 ER - TY - JOUR AU - Plotnikov, A. N. AU - Schlessinger, J. AU - Hubbard, S. R. AU - Mohammadi, M. PY - 1999 DA - 1999// TI - Structural basis for FGF receptor dimerization and activation JO - Cell VL - 98 UR - https://doi.org/10.1016/S0092-8674(00)80051-3 DO - 10.1016/S0092-8674(00)80051-3 ID - Plotnikov1999 ER - TY - JOUR AU - Tenhagen, M. AU - van Diest, P. J. AU - Ivanova, I. A. AU - van der Wall, E. AU - van der Groep, P. PY - 2012 DA - 2012// TI - Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets JO - Endocr Relat Cancer VL - 19 UR - https://doi.org/10.1530/ERC-12-0060 DO - 10.1530/ERC-12-0060 ID - Tenhagen2012 ER - TY - JOUR AU - Babina, I. S. AU - Turner, N. C. PY - 2017 DA - 2017// TI - Advances and challenges in targeting FGFR signalling in cancer JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2017.8 DO - 10.1038/nrc.2017.8 ID - Babina2017 ER - TY - JOUR AU - Courjal, F. AU - Cuny, M. AU - Simony-Lafontaine, J. AU - Louason, G. AU - Speiser, P. AU - Zeillinger, R. PY - 1997 DA - 1997// TI - Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups JO - Cancer Res VL - 57 ID - Courjal1997 ER - TY - JOUR AU - Brunello, E. AU - Brunelli, M. AU - Bogina, G. AU - Caliò, A. AU - Manfrin, E. AU - Nottegar, A. PY - 2012 DA - 2012// TI - FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma JO - J Exp Clin Cancer Res VL - 31 UR - https://doi.org/10.1186/1756-9966-31-103 DO - 10.1186/1756-9966-31-103 ID - Brunello2012 ER - TY - JOUR AU - Hunter, D. J. AU - Kraft, P. AU - Jacobs, K. B. AU - Cox, D. G. AU - Yeager, M. AU - Hankinson, S. E. PY - 2007 DA - 2007// TI - A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer JO - Nat Genet VL - 39 UR - https://doi.org/10.1038/ng2075 DO - 10.1038/ng2075 ID - Hunter2007 ER - TY - JOUR AU - Formisano, L. AU - Stauffer, K. M. AU - Young, C. D. AU - Bhola, N. E. AU - Guerrero-Zotano, A. L. AU - Jansen, V. M. PY - 2017 DA - 2017// TI - Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer JO - Clin Cancer Res VL - 23 UR - https://doi.org/10.1158/1078-0432.CCR-17-1232 DO - 10.1158/1078-0432.CCR-17-1232 ID - Formisano2017 ER - TY - JOUR AU - Marian, C. AU - Ochs-Balcom, H. M. AU - Nie, J. AU - Kallakury, B. V. AU - Ambrosone, C. B. AU - Trevisan, M. PY - 2011 DA - 2011// TI - FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors JO - Int J Cancer VL - 129 UR - https://doi.org/10.1002/ijc.25686 DO - 10.1002/ijc.25686 ID - Marian2011 ER - TY - JOUR AU - Cerliani, J. P. AU - Guillardoy, T. AU - Giulianelli, S. AU - Vaque, J. P. AU - Gutkind, J. S. AU - Vanzulli, S. I. PY - 2011 DA - 2011// TI - Interaction between FGFR-2, STAT5 and progesterone receptors in breast cancer JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-3074 DO - 10.1158/0008-5472.CAN-10-3074 ID - Cerliani2011 ER - TY - JOUR AU - Cerliani, J. P. AU - Vanzulli, S. I. AU - Piñero, C. P. AU - Bottino, M. C. AU - Sahores, A. AU - Nuñez, M. PY - 2012 DA - 2012// TI - Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer JO - Breast Cancer Res Treat VL - 133 UR - https://doi.org/10.1007/s10549-011-1883-6 DO - 10.1007/s10549-011-1883-6 ID - Cerliani2012 ER - TY - JOUR AU - Johnston, C. L. AU - Cox, H. C. AU - Gomm, J. J. AU - Coombes, R. C. PY - 1995 DA - 1995// TI - Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments A splice variant of FGFR-3 localizes to the nucleus JO - J Biol Chem VL - 270 UR - https://doi.org/10.1074/jbc.270.51.30643 DO - 10.1074/jbc.270.51.30643 ID - Johnston1995 ER - TY - JOUR AU - Koziczak, M. AU - Hynes, N. E. PY - 2004 DA - 2004// TI - Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M404252200 DO - 10.1074/jbc.M404252200 ID - Koziczak2004 ER - TY - JOUR AU - Brown, W. S. AU - Akhand, S. S. AU - Wendt, M. K. PY - 2016 DA - 2016// TI - FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.13117 DO - 10.18632/oncotarget.13117 ID - Brown2016 ER - TY - JOUR AU - Tan, S. AU - Ding, K. AU - Chong, Q. Y. AU - Zhao, J. AU - Liu, Y. AU - Shao, Y. PY - 2017 DA - 2017// TI - Decreased miR26a/b and increased HuR expression post-transcriptionally upregulates ERBB2 to mediate acquired tamoxifen resistance in ER+ breast cancer cells JO - J Biol Chem VL - 292 UR - https://doi.org/10.1074/jbc.M117.780973 DO - 10.1074/jbc.M117.780973 ID - Tan2017 ER - TY - JOUR AU - Wang, Y. AU - Zhang, X. AU - Chao, Z. AU - Kung, H. F. AU - Lin, M. C. AU - Dress, A. PY - 2017 DA - 2017// TI - MiR-34a modulates ErbB2 in breast cancer JO - Cell Biol Int VL - 41 UR - https://doi.org/10.1002/cbin.10700 DO - 10.1002/cbin.10700 ID - Wang2017 ER - TY - JOUR AU - He, X. -. H. AU - Zhu, W. AU - Yuan, P. AU - Jiang, S. AU - Li, D. AU - Zhang, H. W. PY - 2016 DA - 2016// TI - miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells JO - Oncogene VL - 35 UR - https://doi.org/10.1038/onc.2016.132 DO - 10.1038/onc.2016.132 ID - He2016 ER - TY - JOUR AU - Du, W. W. AU - Fang, L. AU - Li, M. AU - Yang, X. AU - Liang, Y. AU - Peng, C. PY - 2013 DA - 2013// TI - MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling JO - J Cell Sci VL - 126 UR - https://doi.org/10.1242/jcs.118299 DO - 10.1242/jcs.118299 ID - Du2013 ER - TY - JOUR AU - Choi, B. H. AU - Ryu, D. Y. AU - Ryoo, I. G. AU - Kwak, M. K. PY - 2017 DA - 2017// TI - NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells JO - Oncotarget VL - 8 UR - https://doi.org/10.18632/oncotarget.22513 DO - 10.18632/oncotarget.22513 ID - Choi2017 ER - TY - JOUR AU - Vennin, C. AU - Spruyt, N. AU - Dahmani, F. AU - Julien, S. AU - Bertucci, F. AU - Finetti, P. PY - 2015 DA - 2015// TI - H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b JO - Oncotarget VL - 6 UR - https://doi.org/10.18632/oncotarget.4976 DO - 10.18632/oncotarget.4976 ID - Vennin2015 ER - TY - JOUR AU - Van Grembergen, O. AU - Bizet, M. AU - de Bony, E. J. AU - Calonne, E. AU - Putmans, P. AU - Brohee, S. PY - 2016 DA - 2016// TI - Portraying breast cancer with long noncoding RNAs JO - Sci Adv VL - 2 UR - https://doi.org/10.1126/sciadv.1600220 DO - 10.1126/sciadv.1600220 ID - Van Grembergen2016 ER - TY - JOUR AU - Godinho, M. F. AU - Sieuwerts, A. M. AU - Look, M. P. AU - Meijer, D. AU - Foekens, J. A. AU - Dorssers, L. C. PY - 2010 DA - 2010// TI - Relevance of BCAR4 in tamoxifen resistance and tumor aggressiveness of human breast cancer JO - Br J Cancer VL - 130 UR - https://doi.org/10.1038/sj.bjc.6605884 DO - 10.1038/sj.bjc.6605884 ID - Godinho2010 ER - TY - JOUR AU - Massarweh, S. AU - Osborne, C. K. AU - Creighton, C. J. AU - Qin, L. AU - Tsimelzon, A. AU - Huang, S. PY - 2008 DA - 2008// TI - Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-2707 DO - 10.1158/0008-5472.CAN-07-2707 ID - Massarweh2008 ER - TY - JOUR AU - Osborne, C. K. AU - Schiff, R. PY - 2011 DA - 2011// TI - Mechanisms of endocrine resistance in breast cancer JO - Annu Rev Med VL - 62 UR - https://doi.org/10.1146/annurev-med-070909-182917 DO - 10.1146/annurev-med-070909-182917 ID - Osborne2011 ER - TY - JOUR AU - Ring, A. AU - Dowsett, M. PY - 2004 DA - 2004// TI - Mechanisms of tamoxifen resistance JO - Endocr Relat Cancer VL - 11 UR - https://doi.org/10.1677/erc.1.00776 DO - 10.1677/erc.1.00776 ID - Ring2004 ER - TY - JOUR AU - Schiff, R. AU - Massarweh, S. A. AU - Shou, J. AU - Bharwani, L. AU - Mohsin, S. K. AU - Osborne, C. K. PY - 2004 DA - 2004// TI - Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-031212 DO - 10.1158/1078-0432.CCR-031212 ID - Schiff2004 ER - TY - JOUR AU - García-Becerra, R. AU - Santos, N. AU - Díaz, L. AU - Camacho, J. PY - 2012 DA - 2012// TI - Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance JO - Int J Mol Sci VL - 14 UR - https://doi.org/10.3390/ijms14010108 DO - 10.3390/ijms14010108 ID - García-Becerra2012 ER - TY - JOUR AU - O’Brien, C. S. AU - Howell, S. J. AU - Farnie, G. AU - Clarke, R. B. PY - 2009 DA - 2009// TI - Resistance to endocrine therapy: are breast cancer stem cells the culprits? JO - J Mammary Gland Biol Neoplasia VL - 14 UR - https://doi.org/10.1007/s10911-009-9115-y DO - 10.1007/s10911-009-9115-y ID - O’Brien2009 ER - TY - JOUR AU - Hiscox, S. AU - Baruah, B. AU - Smith, C. AU - Bellerby, R. AU - Goddard, L. AU - Jordan, N. PY - 2012 DA - 2012// TI - Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-458 DO - 10.1186/1471-2407-12-458 ID - Hiscox2012 ER - TY - JOUR AU - Eyler, C. E. AU - Rich, J. N. PY - 2008 DA - 2008// TI - Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.15.1829 DO - 10.1200/JCO.2007.15.1829 ID - Eyler2008 ER - TY - JOUR AU - Bao, B. AU - Mitrea, C. AU - Wijesinghe, P. AU - Marchetti, L. AU - Girsch, E. AU - Farr, R. L. PY - 2017 DA - 2017// TI - Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity JO - Sci Rep VL - 7 UR - https://doi.org/10.1038/srep44125 DO - 10.1038/srep44125 ID - Bao2017 ER - TY - JOUR AU - Robinson, D. R. AU - Wu, Y. M. AU - Vats, P. AU - Su, F. AU - Lonigro, R. J. AU - Cao, X. PY - 2013 DA - 2013// TI - Activating ESR1 mutations in hormone-resistant metastatic breast cancer JO - Nat Genet VL - 45 UR - https://doi.org/10.1038/ng.2823 DO - 10.1038/ng.2823 ID - Robinson2013 ER - TY - JOUR AU - Fu, H. AU - Fu, L. AU - Xie, C. AU - Zuo, W. S. AU - Liu, Y. S. AU - Zheng, M. Z. PY - 2017 DA - 2017// TI - miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer JO - Oncol Rep VL - 37 UR - https://doi.org/10.3892/or.2017.5360 DO - 10.3892/or.2017.5360 ID - Fu2017 ER - TY - JOUR AU - Jin, K. AU - Sukumar, S. PY - 2015 DA - 2015// TI - A pivotal role for HOXB7 protein in endocrine resistant breast cancer JO - Oncoscience VL - 2 ID - Jin2015 ER - TY - JOUR AU - Angus, S. P. AU - Zawistowski, J. S. AU - Johnson, G. L. PY - 2018 DA - 2018// TI - Epigenetic Mechanisms Regulating Adaptive Responses to Targeted Kinase Inhibitors in Cancer JO - Annu Rev Pharmacol Toxicol VL - 58 UR - https://doi.org/10.1146/annurev-pharmtox-010617-052954 DO - 10.1146/annurev-pharmtox-010617-052954 ID - Angus2018 ER - TY - JOUR AU - Nagalingam, A. AU - Tighiouart, M. AU - Ryden, L. AU - Joseph, L. AU - Landberg, G. AU - Saxena, N. K. PY - 2012 DA - 2012// TI - Med1 plays a critical role in the development of tamoxifen resistance JO - Carcinogenesis VL - 33 UR - https://doi.org/10.1093/carcin/bgs105 DO - 10.1093/carcin/bgs105 ID - Nagalingam2012 ER - TY - JOUR AU - Cui, J. AU - Germer, K. AU - Wu, T. AU - Wang, J. AU - Luo, J. AU - Wang, S. C. PY - 2012 DA - 2012// TI - Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-12-1305 DO - 10.1158/0008-5472.CAN-12-1305 ID - Cui2012 ER - TY - JOUR AU - Zelek, L. AU - Barthier, S. AU - Riofrio, M. AU - Fizazi, K. AU - Rixe, O. AU - Delord, J. P. PY - 2001 DA - 2001// TI - Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma JO - Cancer VL - 92 UR - https://doi.org/3.0.CO;2-Q DO - 3.0.CO;2-Q ID - Zelek2001 ER - TY - JOUR AU - Rebucci, M. AU - Michiels, C. PY - 2013 DA - 2013// TI - Molecular aspects of cancer cell resistance to chemotherapy JO - Biochem Pharmacol VL - 85 UR - https://doi.org/10.1016/j.bcp.2013.02.017 DO - 10.1016/j.bcp.2013.02.017 ID - Rebucci2013 ER - TY - JOUR AU - Poole, C. J. AU - Earl, H. M. AU - Hiller, L. AU - Dunn, J. A. AU - Bathers, S. AU - Grieve, R. J. PY - 2006 DA - 2006// TI - Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa052084 DO - 10.1056/NEJMoa052084 ID - Poole2006 ER - TY - JOUR AU - Giuliano, M. AU - Giordano, A. AU - Jackson, S. AU - Hess, K. R. AU - De Giorgi, U. AU - Mego, M. PY - 2011 DA - 2011// TI - Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment JO - Breast Cancer Res VL - 13 UR - https://doi.org/10.1186/bcr2907 DO - 10.1186/bcr2907 ID - Giuliano2011 ER - TY - JOUR AU - Wu, J. AU - Lee, C. AU - Yokom, D. AU - Jiang, H. AU - Cheang, M. C. AU - Yorida, E. PY - 2006 DA - 2006// TI - Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2 JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-3561 DO - 10.1158/0008-5472.CAN-05-3561 ID - Wu2006 ER - TY - JOUR AU - Chen, Y. AU - Simon, S. M. PY - 2000 DA - 2000// TI - In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity JO - J Cell Biol VL - 148 UR - https://doi.org/10.1083/jcb.148.5.863 DO - 10.1083/jcb.148.5.863 ID - Chen2000 ER - TY - JOUR AU - Sinnberg, T. AU - Sauer, B. AU - Holm, P. AU - Spangler, B. AU - Kuphal, S. AU - Bosserhoff, A. PY - 2012 DA - 2012// TI - MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop JO - Exp Dermatol VL - 21 UR - https://doi.org/10.1111/j.1600-0625.2012.01448.x DO - 10.1111/j.1600-0625.2012.01448.x ID - Sinnberg2012 ER - TY - JOUR AU - Lin, E. Y. AU - Pollard, J. W. PY - 2007 DA - 2007// TI - Tumor-associated macrophages press the angiogenic switch in breast cancer JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-0912 DO - 10.1158/0008-5472.CAN-07-0912 ID - Lin2007 ER - TY - JOUR AU - Xuan, Q. J. AU - Wang, J. X. AU - Nanding, A. AU - Wang, Z. P. AU - Liu, H. AU - Lian, X. PY - 2014 DA - 2014// TI - Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients JO - Pathol Oncol Res VL - 20 UR - https://doi.org/10.1007/s12253-013-9740-z DO - 10.1007/s12253-013-9740-z ID - Xuan2014 ER - TY - JOUR AU - Rimawi, M. F. AU - Shetty, P. B. AU - Weiss, H. L. AU - Schiff, R. AU - Osborne, C. K. AU - Chamness, G. C. PY - 2010 DA - 2010// TI - Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24816 DO - 10.1002/cncr.24816 ID - Rimawi2010 ER - TY - JOUR AU - Dai, X. AU - Li, T. AU - Bai, Z. AU - Yang, Y. AU - Liu, X. AU - Zhan, J. PY - 2015 DA - 2015// TI - Breast cancer intrinsic subtype classification, clinical use and future trends JO - Am J Cancer Res VL - 5 ID - Dai2015 ER - TY - JOUR AU - Mirkin, S. AU - Pickar, J. H. PY - 2015 DA - 2015// TI - Selective estrogen receptor modulators (SERMs): a review of clinical data JO - Maturitas VL - 80 UR - https://doi.org/10.1016/j.maturitas.2014.10.010 DO - 10.1016/j.maturitas.2014.10.010 ID - Mirkin2015 ER - TY - JOUR AU - Hudis, C. A. PY - 2007 DA - 2007// TI - Trastuzumab-Mechanism of action and use in clinical practice JO - N Engl J Med VL - 357 UR - https://doi.org/10.1056/NEJMra043186 DO - 10.1056/NEJMra043186 ID - Hudis2007 ER - TY - JOUR AU - Emde, A. AU - Kostler, W. J. AU - Yarden, Y. PY - 2012 DA - 2012// TI - Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer JO - Crit Rev Oncol Hematol VL - 84 UR - https://doi.org/10.1016/j.critrevonc.2010.09.002 DO - 10.1016/j.critrevonc.2010.09.002 ID - Emde2012 ER - TY - JOUR AU - Ahmad, S. AU - Gupta, S. AU - Kumar, R. AU - Varshney, G. C. AU - Raghava, G. P. S. PY - 2014 DA - 2014// TI - Herceptin resistance database for understanding mechanism of resistance in breast cancer patients JO - Sci Rep VL - 4 UR - https://doi.org/10.1038/srep04483 DO - 10.1038/srep04483 ID - Ahmad2014 ER - TY - JOUR AU - Vu, T. AU - Sliwkowski, M. X. AU - Claret, F. X. PY - 2014 DA - 2014// TI - Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer JO - Biochim Biophys Acta VL - 1846 ID - Vu2014 ER - TY - JOUR AU - Teicher, B. A. AU - Doroshow, J. H. PY - 2012 DA - 2012// TI - The promise of antibody-drug conjugates JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMe1211736 DO - 10.1056/NEJMe1211736 ID - Teicher2012 ER - TY - JOUR AU - Verma, S. AU - Miles, D. AU - Gianni, L. AU - Krop, I. E. AU - Welslau, M. AU - Baselga, J. PY - 2012 DA - 2012// TI - Trastuzumabemtansine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1209124 DO - 10.1056/NEJMoa1209124 ID - Verma2012 ER - TY - JOUR AU - Perez, E. A. AU - Barrios, C. AU - Eiermann, W. AU - Toi, M. AU - Im, Y. H. AU - Conte, P. PY - 2017 DA - 2017// TI - Trastuzumabemtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2–positive, advanced breast cancer: primary results from the phase III MARIANNE study JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.67.4887 DO - 10.1200/JCO.2016.67.4887 ID - Perez2017 ER - TY - JOUR AU - Baselga, J. AU - Cortés, J. AU - Kim, S. B. AU - Im, S. A. AU - Hegg, R. AU - Im, Y. H. PY - 2012 DA - 2012// TI - Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1113216 DO - 10.1056/NEJMoa1113216 ID - Baselga2012 ER - TY - JOUR AU - Swain, S. M. AU - Baselga, J. AU - Kim, S. B. AU - Ro, J. AU - Semiglazov, V. AU - Campone, M. PY - 2015 DA - 2015// TI - Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1413513 DO - 10.1056/NEJMoa1413513 ID - Swain2015 ER - TY - JOUR AU - Moreira, C. AU - Kaklamani, V. PY - 2010 DA - 2010// TI - Lapatinib and breast cancer: current indications and outlook for the future JO - Expert Rev Anticancer Ther VL - 10 UR - https://doi.org/10.1586/era.10.113 DO - 10.1586/era.10.113 ID - Moreira2010 ER - TY - JOUR AU - Blackwell, K. L. AU - Burstein, H. J. AU - Storniolo, A. M. AU - Rugo, H. AU - Sledge, G. AU - Koehler, M. PY - 2010 DA - 2010// TI - Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2008.21.4437 DO - 10.1200/JCO.2008.21.4437 ID - Blackwell2010 ER - TY - JOUR AU - Johnston, S. AU - Pippen, J. AU - Pivot, X. AU - Lichinitser, M. AU - Sadeghi, S. AU - Dieras, V. PY - 2009 DA - 2009// TI - Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.23.3734 DO - 10.1200/JCO.2009.23.3734 ID - Johnston2009 ER - TY - JOUR AU - Geyer, C. E. AU - Forster, J. AU - Lindquist, D. AU - Chan, S. AU - Romieu, C. G. AU - Pienkowski, T. PY - 2006 DA - 2006// TI - Lapatinib plus capecitabine for HER2-positive advanced breast cancer JO - N Engl J Med VL - 355 UR - https://doi.org/10.1056/NEJMoa064320 DO - 10.1056/NEJMoa064320 ID - Geyer2006 ER - TY - JOUR AU - von Minckwitz, G. AU - Jonat, W. AU - Fasching, P. AU - du Bois, A. AU - Kleeberg, U. AU - Luck, H. J. PY - 2005 DA - 2005// TI - A multicentre phase II study on gefitinib in tax¬ane- and anthracycline-pretreated metastatic breast cancer JO - Breast Cancer Res Treat VL - 89 UR - https://doi.org/10.1007/s10549-004-1720-2 DO - 10.1007/s10549-004-1720-2 ID - von Minckwitz2005 ER - TY - JOUR AU - Baselga, J. AU - Albanell, J. AU - Ruiz, A. AU - Lluch, A. AU - Gascon, P. AU - Guillem, V. PY - 2005 DA - 2005// TI - Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.08.326 DO - 10.1200/JCO.2005.08.326 ID - Baselga2005 ER - TY - JOUR AU - Dickler, M. N. AU - Cobleigh, M. A. AU - Miller, K. D. AU - Klein, P. M. AU - Winer, E. P. PY - 2009 DA - 2009// TI - Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer JO - Breast Cancer Res Treat VL - 115 UR - https://doi.org/10.1007/s10549-008-0055-9 DO - 10.1007/s10549-008-0055-9 ID - Dickler2009 ER - TY - JOUR AU - Bernsdorf, M. AU - Ingvar, C. AU - Jorgensen, L. AU - Tuxen, M. K. AU - Jakobsen, E. H. AU - Saetersdal, A. PY - 2011 DA - 2011// TI - Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial JO - Breast Cancer Res Treat VL - 126 UR - https://doi.org/10.1007/s10549-011-1352-2 DO - 10.1007/s10549-011-1352-2 ID - Bernsdorf2011 ER - TY - JOUR AU - Schuler, M. AU - Awada, A. AU - Harter, P. AU - Canon, J. L. AU - Possinger, K. AU - Schmidt, M. PY - 2012 DA - 2012// TI - A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer JO - Breast Cancer Res Treat VL - 134 UR - https://doi.org/10.1007/s10549-012-2126-1 DO - 10.1007/s10549-012-2126-1 ID - Schuler2012 ER - TY - JOUR AU - Carey, L. A. AU - Rugo, H. S. AU - Marcom, P. K. AU - Mayer, E. L. AU - Esteva, F. J. AU - Ma, C. X. PY - 2012 DA - 2012// TI - TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2010.34.5579 DO - 10.1200/JCO.2010.34.5579 ID - Carey2012 ER - TY - JOUR AU - Baselga, J. AU - Gomez, P. AU - Greil, R. AU - Braga, S. AU - Climent, M. A. AU - Wardley, A. M. PY - 2013 DA - 2013// TI - Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.46.2408 DO - 10.1200/JCO.2012.46.2408 ID - Baselga2013 ER - TY - JOUR AU - Tredan, O. AU - Campone, M. AU - Jassem, J. AU - Vyzula, R. AU - Coudert, B. AU - Pacilio, C. PY - 2015 DA - 2015// TI - Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer JO - Clin Breast Cancer VL - 15 UR - https://doi.org/10.1016/j.clbc.2014.07.007 DO - 10.1016/j.clbc.2014.07.007 ID - Tredan2015 ER - TY - JOUR AU - Crozier, J. A. AU - Advani, P. P. AU - LaPlant, B. AU - Hobday, T. AU - Jaslowski, A. J. AU - Moreno-Aspitia, A. PY - 2016 DA - 2016// TI - N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthra-cycline and/or Taxane-Containing Therapy JO - Clin Breast Cancer VL - 16 UR - https://doi.org/10.1016/j.clbc.2015.08.002 DO - 10.1016/j.clbc.2015.08.002 ID - Crozier2016 ER - TY - JOUR AU - Nabholtz, J. M. AU - Abrial, C. AU - Mouret-Reynier, M. A. AU - Dauplat, M. M. AU - Weber, B. AU - Gligorov, J. PY - 2014 DA - 2014// TI - Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu183 DO - 10.1093/annonc/mdu183 ID - Nabholtz2014 ER - TY - JOUR AU - Nabholtz, J. M. AU - Chalabi, N. AU - Radosevic-Robin, N. AU - Dauplat, M. M. AU - Mouret-Reynier, M. A. AU - Van Praagh, I. PY - 2016 DA - 2016// TI - Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer JO - Int J Cancer VL - 138 UR - https://doi.org/10.1002/ijc.29952 DO - 10.1002/ijc.29952 ID - Nabholtz2016 ER - TY - JOUR AU - Cowherd, S. AU - Miller, L. D. AU - Melin, S. A. AU - Akman, S. AU - Isom, S. AU - Cole, J. PY - 2015 DA - 2015// TI - A phase ii clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer JO - Cancer Biol Ther VL - 16 UR - https://doi.org/10.1080/15384047.2015.1026481 DO - 10.1080/15384047.2015.1026481 ID - Cowherd2015 ER - TY - JOUR AU - Layman, R. M. AU - Ruppert, A. S. AU - Lynn, M. AU - Mrozek, E. AU - Ramaswamy, B. AU - Lustberg, M. B. PY - 2013 DA - 2013// TI - Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer JO - Cancer Chemother Pharmacol VL - 71 UR - https://doi.org/10.1007/s00280-013-2112-2 DO - 10.1007/s00280-013-2112-2 ID - Layman2013 ER - TY - JOUR AU - Miles, D. AU - Cameron, D. AU - Bondarenko, I. AU - Manzyuk, L. AU - Alcedo, J. C. AU - Lopez, R. I. PY - 2017 DA - 2017// TI - Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation JO - Eur J Cancer VL - 70 UR - https://doi.org/10.1016/j.ejca.2016.09.024 DO - 10.1016/j.ejca.2016.09.024 ID - Miles2017 ER - TY - JOUR AU - Gligorov, J. AU - Doval, D. AU - Bines, J. AU - Alba, E. AU - Cortes, P. AU - Pierga, J. -. Y. PY - 2014 DA - 2014// TI - Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70444-9 DO - 10.1016/S1470-2045(14)70444-9 ID - Gligorov2014 ER - TY - JOUR AU - Bergh, J. AU - Bondarenko, I. M. AU - Lichinitser, M. R. AU - Liljegren, A. AU - Greil, R. AU - Voytko, N. L. PY - 2012 DA - 2012// TI - First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.35.7376 DO - 10.1200/JCO.2011.35.7376 ID - Bergh2012 ER - TY - JOUR AU - De, P. AU - Hasmann, M. AU - Leyland-Jones, B. PY - 2013 DA - 2013// TI - Molecular determinants of trastuzumab efficacy: what is their clinical relevance? JO - Cancer Treat Rev VL - 39 UR - https://doi.org/10.1016/j.ctrv.2013.02.006 DO - 10.1016/j.ctrv.2013.02.006 ID - De2013 ER - TY - JOUR AU - Roberti, M. P. AU - Rocca, Y. S. AU - Amat, M. AU - Pampena, M. B. AU - Loza, J. AU - Coló, F. PY - 2012 DA - 2012// TI - IL-2-or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients JO - Breast Cancer Res Treat VL - 136 UR - https://doi.org/10.1007/s10549-012-2287-y DO - 10.1007/s10549-012-2287-y ID - Roberti2012 ER - TY - JOUR AU - El Guerrab, A. AU - Bamdad, M. AU - Bignon, Y. J. AU - Penault-Llorca, F. AU - Aubel, C. PY - 2017 DA - 2017// TI - Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells JO - Mol Carcinog VL - 56 UR - https://doi.org/10.1002/mc.22596 DO - 10.1002/mc.22596 ID - El Guerrab2017 ER - TY - JOUR AU - Mazorra, Z. AU - Lavastida, A. AU - Concha-Benavente, F. AU - Valdés, A. AU - Srivastava, R. M. AU - García-Bates, T. M. PY - 2017 DA - 2017// TI - Nimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients JO - Front Pharmacol VL - 8 UR - https://doi.org/10.3389/fphar.2017.00382 DO - 10.3389/fphar.2017.00382 ID - Mazorra2017 ER - TY - JOUR AU - Dienstmann, R. AU - Tabernero, J. PY - 2010 DA - 2010// TI - Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer JO - Curr Opin Investig Drugs VL - 11 ID - Dienstmann2010 ER - TY - JOUR AU - Zhang, X. AU - Zhang, B. AU - Liu, J. AU - Liu, J. AU - Li, C. AU - Dong, W. PY - 2015 DA - 2015// TI - Mechanisms of gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression JO - Sci Rep VL - 5 UR - https://doi.org/10.1038/srep07835 DO - 10.1038/srep07835 ID - Zhang2015 ER - TY - JOUR AU - Yamasaki, F. AU - Zhang, D. AU - Bartholomeusz, C. AU - Sudo, T. AU - Hortobagyi, G. N. AU - Kurisu, K. PY - 2007 DA - 2007// TI - Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity JO - Mol Cancer Ther VL - 6 UR - https://doi.org/10.1158/1535-7163.MCT-06-0514 DO - 10.1158/1535-7163.MCT-06-0514 ID - Yamasaki2007 ER - TY - JOUR AU - Hurvitz, S. A. AU - Shatsky, R. AU - Harbeck, N. PY - 2014 DA - 2014// TI - Afatinib in the treatment of breast cancer JO - Expert Opin Investig Drugs VL - 23 UR - https://doi.org/10.1517/13543784.2014.924505 DO - 10.1517/13543784.2014.924505 ID - Hurvitz2014 ER - TY - STD TI - Liu CY, Huang TT, Huang CT, Yang HP, Tseng LM, Shiau CW, et al. Pan-HER inhibitor, varlitinib, disrupts HER/ERK signaling and causes apoptosis in triple-negative breast. Cancer Cells. 2017; https://doi.org/10.1158/1538-7445.AM2017-2087. ID - ref167 ER - TY - JOUR AU - Kalous, O. AU - Conklin, D. AU - Desai, A. J. AU - O'Brien, N. A. AU - Ginther, C. AU - Anderson, L. PY - 2012 DA - 2012// TI - Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib JO - Mol CancerTher VL - 11 ID - Kalous2012 ER - TY - JOUR AU - Morrison, G. AU - Fu, X. AU - Shea, M. AU - Nanda, S. AU - Giuliano, M. AU - Wang, T. PY - 2014 DA - 2014// TI - Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance JO - Breast Cancer Res Treat VL - 144 UR - https://doi.org/10.1007/s10549-014-2878-x DO - 10.1007/s10549-014-2878-x ID - Morrison2014 ER - TY - JOUR AU - Morabito, A. AU - Piccirillo, M. C. AU - Falasconi, F. AU - De Feo, G. AU - Del Giudice, A. AU - Bryce, J. PY - 2009 DA - 2009// TI - Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions JO - Oncologist VL - 14 UR - https://doi.org/10.1634/theoncologist.2008-0261 DO - 10.1634/theoncologist.2008-0261 ID - Morabito2009 ER - TY - JOUR AU - Echavarria, I. AU - López-Tarruella, S. AU - Márquez-Rodas, I. AU - Jerez, Y. AU - Martin, M. PY - 2017 DA - 2017// TI - Neratinib for the treatment of HER2-positive early stage breast cancer JO - Expert Rev Anticancer Ther VL - 7 UR - https://doi.org/10.1080/14737140.2017.1338954 DO - 10.1080/14737140.2017.1338954 ID - Echavarria2017 ER - TY - JOUR AU - Wong, T. W. AU - Lee, F. Y. AU - Emanuel, S. AU - Fairchild, C. AU - Fargnoli, J. AU - Fink, B. PY - 2011 DA - 2011// TI - Antitumor and antiangiogenic activities of BMS-690514, an inhibitor of human EGF and VEGF receptor kinase families JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-3417 DO - 10.1158/1078-0432.CCR-10-3417 ID - Wong2011 ER - TY - JOUR AU - Traxler, P. AU - Allegrini, P. R. AU - Brandt, R. AU - Brueggen, J. AU - Cozens, R. AU - Fabbro, D. PY - 2004 DA - 2004// TI - AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-03-3681 DO - 10.1158/0008-5472.CAN-03-3681 ID - Traxler2004 ER - TY - STD TI - Nguyen M, Lin KK, Burbridge MF, Simmons AD, Harding TC. Abstract 784: Nonclinical activity of the FGFR, VEGFR and PDGFR inhibitor lucitanib in FGFR3 translocated tumor models. Cancer Res. 2015; https://doi.org/10.1158/1538-7445.AM2015-784. ID - ref174 ER - TY - JOUR AU - Ferrara, N. AU - Hillan, K. J. AU - Gerber, H. P. AU - Novotny, W. PY - 2004 DA - 2004// TI - Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer JO - Nat Rev Drug Discov VL - 3 UR - https://doi.org/10.1038/nrd1381 DO - 10.1038/nrd1381 ID - Ferrara2004 ER - TY - JOUR AU - Ferrer-Soler, L. AU - Vazquez-Martin, A. AU - Brunet, J. AU - Menendez, J. A. AU - De Llorens, R. AU - Colomer, R. PY - 2007 DA - 2007// TI - An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa™)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands JO - Int J Mol Med VL - 20 ID - Ferrer-Soler2007 ER - TY - JOUR AU - Chell, V. AU - Balmanno, K. AU - Little, A. S. AU - Wilson, M. AU - Andrews, S. AU - Blockley, L. PY - 2013 DA - 2013// TI - Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance JO - Oncogene VL - 32 UR - https://doi.org/10.1038/onc.2012.319 DO - 10.1038/onc.2012.319 ID - Chell2013 ER - TY - JOUR AU - Luo, M. AU - Fu, L. W. PY - 2014 DA - 2014// TI - Redundant kinase activation and resistance of EGFR-tyrosine kinase inhibitors JO - Am J Cancer Res VL - 4 ID - Luo2014 ER - TY - JOUR AU - Rexer, B. N. AU - Arteaga, C. L. PY - 2012 DA - 2012// TI - Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications JO - Crit Rev Oncog VL - 17 UR - https://doi.org/10.1615/CritRevOncog.v17.i1.20 DO - 10.1615/CritRevOncog.v17.i1.20 ID - Rexer2012 ER - TY - JOUR AU - Shattuck, D. L. AU - Miller, J. K. AU - Carraway, K. L. AU - Sweeney, C. PY - 2008 DA - 2008// TI - Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-5962 DO - 10.1158/0008-5472.CAN-07-5962 ID - Shattuck2008 ER - TY - JOUR AU - Mueller, K. L. AU - Hunter, L. A. AU - Ethier, S. P. AU - Boerner, J. L. PY - 2008 DA - 2008// TI - Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-0132 DO - 10.1158/0008-5472.CAN-08-0132 ID - Mueller2008 ER - TY - JOUR AU - Tomlinson, D. C. AU - Knowles, M. A. AU - Speirs, V. PY - 2012 DA - 2012// TI - Mechanisms of FGFR3 actions in endocrine resistant breast cancer JO - Int J Cancer VL - 130 UR - https://doi.org/10.1002/ijc.26304 DO - 10.1002/ijc.26304 ID - Tomlinson2012 ER - TY - JOUR AU - Mukohara, T. PY - 2015 DA - 2015// TI - PI3K mutations in breast cancer: prognostic and therapeutic implications JO - Breast Cancer (Dove Med Press) VL - 7 ID - Mukohara2015 ER - TY - JOUR AU - Bottsford-Miller, J. N. AU - Coleman, R. L. AU - Sood, A. K. PY - 2012 DA - 2012// TI - Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.41.9242 DO - 10.1200/JCO.2012.41.9242 ID - Bottsford-Miller2012 ER - TY - JOUR AU - Shojaei, F. AU - Ferrara, N. PY - 2008 DA - 2008// TI - Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-0925 DO - 10.1158/0008-5472.CAN-08-0925 ID - Shojaei2008 ER - TY - JOUR AU - Ghatak, S. AU - Misra, S. AU - Toole, B. P. PY - 2002 DA - 2002// TI - Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway JO - J Biol Chem VL - 277 UR - https://doi.org/10.1074/jbc.M202404200 DO - 10.1074/jbc.M202404200 ID - Ghatak2002 ER - TY - JOUR AU - Pályi-Krekk, Z. AU - Barok, M. AU - Isola, J. AU - Tammi, M. AU - Szöllo, J. AU - Nagy, P. PY - 2007 DA - 2007// TI - Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2007.08.018 DO - 10.1016/j.ejca.2007.08.018 ID - Pályi-Krekk2007 ER - TY - JOUR AU - Chandarlapaty, S. AU - Scaltriti, M. AU - Angelini, P. AU - Ye, Q. AU - Guzman, M. AU - Hudis, C. A. PY - 2010 DA - 2010// TI - Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2009.337 DO - 10.1038/onc.2009.337 ID - Chandarlapaty2010 ER - TY - JOUR AU - Ozkavruk Eliyatkin, N. AU - Aktas, S. AU - Ozgur, H. AU - Ercetin, P. AU - Kupelioglu, A. PY - 2016 DA - 2016// TI - The role of p95HER2 in trastuzumab resistance in breast cancer JO - J BUON VL - 21 ID - Ozkavruk Eliyatkin2016 ER - TY - JOUR AU - Rexer, B. N. AU - Ghosh, R. AU - Narasanna, A. AU - Estrada, M. V. AU - Chakrabarty, A. AU - Song, Y. PY - 2013 DA - 2013// TI - Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2 JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-1038 DO - 10.1158/1078-0432.CCR-13-1038 ID - Rexer2013 ER - TY - JOUR AU - Hanker, A. B. AU - Brewer, M. R. AU - Sheehan, J. H. AU - Koch, J. P. AU - Sliwoski, G. R. AU - Nagy, R. PY - 2017 DA - 2017// TI - An acquired HER2 T798I gatekeeper mutation induces resistance to Neratinib in a patient with HER2 mutant–driven breast cancer JO - Cancer Discov VL - 7 UR - https://doi.org/10.1158/2159-8290.CD-16-1431 DO - 10.1158/2159-8290.CD-16-1431 ID - Hanker2017 ER -